Cabaletta Bio to Participate in Guggenheim’s Inaugural Healthcare Innovation Conference

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

PHILADELPHIA, Nov. 06, 2024 (GLOBE NEWSWIRE) — Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies designed specifically for patients with autoimmune diseases, today announced that the Company will participate in a fireside chat at Guggenheim’s Inaugural Healthcare Innovation Conference on Monday, November 11, 2024, at 10:00 a.m. ET in Boston, MA.

A live webcast of the presentation will be available on the News and Events section of the Company’s website at www.cabalettabio.com. Replays will be available on the website for 30 days.

About Cabaletta Bio
Cabaletta Bio (Nasdaq: CABA) is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies that have the potential to provide a deep and durable, perhaps curative, treatment for patients with autoimmune diseases. The CABA™ platform encompasses two strategies: the CARTA (chimeric antigen receptor T cells for autoimmunity) strategy, with CABA-201, a 4-1BB-containing fully human CD19-CAR T, as the lead product candidate being evaluated in the RESET™ (REstoring SElf-Tolerance) clinical trials in myositis, systemic lupus erythematosus, systemic sclerosis, generalized myasthenia gravis and in the RESET-PV™ sub-study within the DesCAARTes™ clinical trial in pemphigus vulgaris, along with the CAART (chimeric autoantibody receptor T cells) strategy, with multiple clinical-stage candidates, including DSG3-CAART for mucosal pemphigus vulgaris and MuSK-CAART for MuSK-associated myasthenia gravis. The expanding CABA™ platform is designed to develop potentially curative therapies that offer deep and durable responses for patients with a broad range of autoimmune diseases. Cabaletta Bio’s headquarters and labs are located in Philadelphia, PA.

Contacts:

Anup Marda
Chief Financial Officer
investors@cabalettabio.com

William Gramig
Precision AQ
william.gramig@precisionaq.com

Staff

Recent Posts

SmartSKN Launches K-OWN: The World’s first AI custom Korean skincare platform powered by robots

BOSTON, March 14, 2025 /PRNewswire/ -- SmartSKN, a leader in K-Beauty technology, announces the launch…

10 hours ago

Nimblemind.ai Raises $2.5M to Unlock AI-Ready Clinical Data for Healthcare Providers

CHICAGO, March 14, 2025 /PRNewswire/ -- Nimblemind.ai, an AI-powered data infrastructure platform designed to help…

11 hours ago

AI-Powered Healthcare: How ADLINK’s Medical Innovations at HIMSS 2025 Are Transforming Patient Care

Celebrating 30 Years of Innovation Excellence with Advanced OEM Solutions for Healthcare Summary: Successful Showcase:…

11 hours ago

CTG Appoints Dan Stoke Vice President of U.S. Healthcare Business

Growth-Oriented Healthcare IT Leader to Build on CTG’s Strong Industry Legacy; Drive Growth, Innovation, and…

13 hours ago

TruBridge Announces Participation in the KeyBanc Capital Markets Healthcare Forum

MOBILE, Ala.--(BUSINESS WIRE)--TruBridge, Inc. (NASDAQ:TBRG), a healthcare solutions company, today announced that management will participate…

13 hours ago

WTWH Healthcare, a WTWH Media Company, Announces 2025 Aspect Awards Winners

CLEVELAND, March 14, 2025 /PRNewswire/ -- WTWH Healthcare, a WTWH Media company, is proud to…

16 hours ago